{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:27:46Z","timestamp":1770420466762,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ahjo.2025.100623","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:45:44Z","timestamp":1758620744000},"page":"100623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia"],"prefix":"10.1016","volume":"59","author":[{"given":"Minimize","family":"Hassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birhane Tilahun","family":"Worku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tewodros","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulat Belete","family":"Demessie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teklehaimanot Fentie","family":"Wendie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumer Sada","family":"Muhammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengistie Yirsaw","family":"Gobezie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2025.100623_bb0005","doi-asserted-by":"crossref","first-page":"18899","DOI":"10.1038\/s41598-022-23700-0","article-title":"Treatment burden among patients with heart failure attending cardiac clinic of Tikur Anbessa Specialized Hospital: an explanatory sequential mixed methods study","volume":"12","author":"Hassen","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ahjo.2025.100623_bb0010","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2025.100623_bb0015","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2025.100623_bb0020","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ahjo.2025.100623_bb0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2025.100623_bb0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahjo.2025.100623_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahjo.2025.100623_bb0040","article-title":"Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center","volume":"17","author":"Bradley","year":"2019","journal-title":"Pharm. Pract."},{"key":"10.1016\/j.ahjo.2025.100623_bb0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0050","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0055","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ejhf.496","article-title":"Use of evidence-based therapy and survival in heart failure in Sweden 2003\u20132012","volume":"18","author":"Thorvaldsen","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2025.100623_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258949","article-title":"Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function","volume":"16","author":"Jonsson Holmdahl","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.ahjo.2025.100623_bb0070","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejhf.13","article-title":"Worsening renal function during renin\u2013angiotensin\u2013aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction","volume":"16","author":"Clark","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0080","series-title":"Aldosterone Antagonists: Evidence-based Yet Underutilized Effective Heart Failure Therapy","first-page":"105","volume":"19","author":"Lavie","year":"2013"},{"key":"10.1016\/j.ahjo.2025.100623_bb0085","first-page":"188","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0090","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2025.100623_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.amjcard.2021.04.017","article-title":"Role of guideline directed medical therapy doses and optimization in patients hospitalized with decompensated systolic heart failure","volume":"151","author":"Grewal","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2025.100623_bb0100","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0018578717724886","article-title":"Underutilization of aldosterone antagonists in heart failure","volume":"52","author":"Patterson","year":"2017","journal-title":"Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ahjo.2025.100623_bb0105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ejhf.2441","article-title":"A promise unfulfilled: the use of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction","volume":"24","author":"Pitt","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2025.100623_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12471-021-01591-6","article-title":"Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction","volume":"29","author":"Nauta","year":"2021","journal-title":"Netherlands Heart Journal"},{"key":"10.1016\/j.ahjo.2025.100623_bb0115","first-page":"481","article-title":"Angiotensin-converting enzyme inhibitor dose optimization and its associated factors at Felege Hiwot comprehensive specialized hospital, Bahir Dar, Ethiopia","author":"Gelaye","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ahjo.2025.100623_bb0120","doi-asserted-by":"crossref","first-page":"15903","DOI":"10.1038\/s41598-020-72836-4","article-title":"Treatment optimization of beta-blockers in chronic heart failure therapy","volume":"10","author":"Niriayo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ahjo.2025.100623_bb0125","doi-asserted-by":"crossref","first-page":"9463872","DOI":"10.1155\/2019\/9463872","article-title":"Utilization and dose optimization of angiotensin-converting enzyme inhibitors among heart failure patients in Southwest Ethiopia","volume":"2019","author":"Niriayo","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ahjo.2025.100623_bb0130","first-page":"21","article-title":"Utilization and optimization of Beta-blockers on heart failure patients with reduced ejection fraction (HFrEF) at cardiac clinic of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a cross-sectional study","author":"Demissie","year":"2023","journal-title":"Res. Rep. Clin. Cardiol."},{"key":"10.1016\/j.ahjo.2025.100623_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33140\/AJUN.06.01.04","article-title":"Risk factors of chronic kidney disease among patients attending at Dessie Comprehensive Specialized Hospital, Dessie, Amhara Region, Northeastern Ethiopia: unmatched case\u2013control study","volume":"6","author":"Yimer","year":"2024","journal-title":"Advancements in Journal of Urology and Nephrology"},{"key":"10.1016\/j.ahjo.2025.100623_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00129784-200707010-00007","article-title":"Aldosterone antagonists: the most underutilized class of heart failure medications","volume":"7","author":"Guglin","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ahjo.2025.100623_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-1175-3","article-title":"Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study","volume":"19","author":"Durstenfeld","year":"2019","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ahjo.2025.100623_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2710.2004.00549.x","article-title":"Spironolactone use in patients with heart failure","volume":"29","author":"Trujillo","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ahjo.2025.100623_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002268","article-title":"Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure","volume":"4","author":"Dev","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ahjo.2025.100623_bb0160","article-title":"Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population","volume":"9","author":"Holmdahl","year":"2022","journal-title":"Open heart"},{"key":"10.1016\/j.ahjo.2025.100623_bb0165","first-page":"15","article-title":"Guidelines on clinical and programmatic management of major non communicable diseases","volume":"1","author":"Walelgne","year":"2016","journal-title":"Addis Ababa: Federal Democratic Republic of Ethiopia Ministry of Health"},{"key":"10.1016\/j.ahjo.2025.100623_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease","volume":"6","author":"Cooper","year":"2017","journal-title":"J. Am. Heart Assoc."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602225001260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602225001260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:16:25Z","timestamp":1770380185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602225001260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S2666602225001260"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2025.100623","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2025.100623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100623"}}